M. Brandely

1.0k total citations
36 papers, 760 citations indexed

About

M. Brandely is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Brandely has authored 36 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 15 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Brandely's work include Immune Cell Function and Interaction (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Immunotherapy and Immune Responses (5 papers). M. Brandely is often cited by papers focused on Immune Cell Function and Interaction (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Immunotherapy and Immune Responses (5 papers). M. Brandely collaborates with scholars based in France, Italy and Netherlands. M. Brandely's co-authors include Nicoletta Colombo, Didier Blaise, D Maraninchi, A. M. Stoppa, C Boutin, Josy Reiffers, Gérald Marit, J. R. Viallat, Patrice Viens and Daniel Olive and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

M. Brandely

35 papers receiving 731 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Brandely France 14 326 262 164 138 119 36 760
Gerald L. Messerschmidt United States 12 166 0.5× 175 0.7× 123 0.8× 59 0.4× 115 1.0× 26 559
Narelle Woodland Australia 9 466 1.4× 276 1.1× 323 2.0× 58 0.4× 165 1.4× 14 799
Minish Jain United States 14 275 0.8× 459 1.8× 61 0.4× 155 1.1× 258 2.2× 68 828
S. N. Markovic United States 8 203 0.6× 352 1.3× 73 0.4× 85 0.6× 123 1.0× 25 618
S Nagashima United States 9 255 0.8× 145 0.6× 25 0.2× 46 0.3× 150 1.3× 14 534
Yabing Cao China 15 144 0.4× 350 1.3× 39 0.2× 135 1.0× 191 1.6× 52 811
A Rambaldi United States 7 288 0.9× 138 0.5× 236 1.4× 27 0.2× 120 1.0× 8 560
Meili Ge China 14 261 0.8× 81 0.3× 360 2.2× 35 0.3× 93 0.8× 69 630
Maria Spyropoulou‐Vlachou Greece 13 368 1.1× 138 0.5× 239 1.5× 58 0.4× 189 1.6× 26 676
Nicole Izykowski Germany 12 82 0.3× 130 0.5× 33 0.2× 182 1.3× 115 1.0× 14 548

Countries citing papers authored by M. Brandely

Since Specialization
Citations

This map shows the geographic impact of M. Brandely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Brandely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Brandely more than expected).

Fields of papers citing papers by M. Brandely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Brandely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Brandely. The network helps show where M. Brandely may publish in the future.

Co-authorship network of co-authors of M. Brandely

This figure shows the co-authorship network connecting the top 25 collaborators of M. Brandely. A scholar is included among the top collaborators of M. Brandely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Brandely. M. Brandely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kitzen, Jos, Maja J.A. de Jonge, C. B. H. W. Lamers, et al.. (2009). Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. European Journal of Cancer. 45(10). 1764–1772. 77 indexed citations
3.
Nolè, Franco, Diana Crivellari, Rodolfo Mattioli, et al.. (2009). Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 64(4). 673–680. 29 indexed citations
4.
Delord, Jean‐Pierre, et al.. (2007). Absolute bioavailability of an oral form of vinflunine, a first phase I trial. Molecular Cancer Therapeutics. 6. 1 indexed citations
5.
Serin, D., Mark Verrill, Andrew Jones, et al.. (2005). Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. British Journal of Cancer. 92(11). 1989–1996. 10 indexed citations
6.
Blaise, Didier, Michel Attal, Josy Reiffers, et al.. (2000). Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.. PubMed. 11(1). 91–8. 52 indexed citations
7.
Vey, Norbert, Patrice Viens, C. Fossat, et al.. (1997). Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.. PubMed. 8(4). 389–94. 5 indexed citations
8.
Pujade-Lauraine, Éric, Jean‐Paul Guastalla, Nicoletta Colombo, et al.. (1996). Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.. Journal of Clinical Oncology. 14(2). 343–350. 130 indexed citations
9.
Valteau-Couanet, D, H Rubie, Valérie Méresse, et al.. (1995). Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.. PubMed. 16(4). 515–20. 19 indexed citations
10.
Thiounn, Nicolas, Claire Mathiot, Éric Tartour, et al.. (1994). Phenotypic and Functional Analysis of Tumour-lnfiltrating Lymphocytes from Patients with Renal Cell Carcinoma. European Urology. 25(2). 151–157. 2 indexed citations
11.
Viallat, J. R., et al.. (1993). Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer. 71(12). 4067–4071. 24 indexed citations
12.
Escudier, Bernard, S. Antoun, B. Leclercq, et al.. (1993). Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. European Journal of Cancer. 29(5). 724–728. 21 indexed citations
13.
Blétry, O, J. Cabané, Clara Giménez Francés, et al.. (1993). Résultats à long terme du traitement des sclérodermies systémiques diffuses par l'interféron gamma. La Revue de Médecine Interne. 14(10). 978–978. 5 indexed citations
14.
Bachouchi, M., Jean‐Nicolas Munck, Pierre Busson, et al.. (1993). Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head & Neck. 15(2). 115–118. 10 indexed citations
15.
Viens, Patrice, Didier Blaise, A.-M. Stoppa, et al.. (1992). Interleukin-2 in Association with Increasing Doses of Interferon-Gamma in Patients with Advanced Cancer. Journal of Immunotherapy. 11(3). 218–224. 3 indexed citations
16.
Colombo, Nicoletta, Fedro A. Peccatori, C Paganin, et al.. (1992). Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy. International Journal of Cancer. 51(1). 42–46. 61 indexed citations
17.
Dorval, Thierry, Claire Mathiot, O. Chosidow, et al.. (1992). IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.. PubMed. 3(1-2). 63–79. 16 indexed citations
18.
Mathiot, Claire, Elodie Robin, Alain Gey, et al.. (1992). Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. European Journal of Cancer. 28(2-3). 345–350. 8 indexed citations
19.
Maraninchi, D, Didier Blaise, Patrice Viens, et al.. (1991). High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 78(9). 2182–2187. 78 indexed citations
20.
Boutin, C, J. R. Viallat, Nico van Zandwijk, et al.. (1991). Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer. 67(8). 2033–2037. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerald L. Messerschmidt Breakdown of academic impact, for papers by Narelle Woodland Breakdown of academic impact, for papers by Minish Jain Breakdown of academic impact, for papers by S. N. Markovic Breakdown of academic impact, for papers by S Nagashima Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by A Rambaldi Breakdown of academic impact, for papers by Meili Ge Breakdown of academic impact, for papers by Maria Spyropoulou‐Vlachou Breakdown of academic impact, for papers by Nicole Izykowski
Rankless by CCL
2026